Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 12/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348080 | 0.88 | NLRP3 (0.44) | AKR1B1NLRP3ALOX15MAPT | |
| SCHEMBL24077185 | 0.87 | GAA (0.48) | NLRP3MAPT | |
| SCHEMBL30039545 | 0.87 | GAA (0.48) | NLRP3MAPT | |
| SCHEMBL29348082 | 0.85 | NLRP3 (0.42) | AKR1B1NLRP3ALOX15MAPTRAB9A | |
| SCHEMBL24076315 | 0.81 | ALOX15 (0.64) | AKR1B1NLRP3ALOX15AKR1B10AKR1A1 | |
| SCHEMBL24077200 | 0.81 | AKR1B1 (0.47) | AKR1B1NLRP3ALOX15MAPT | |
| SCHEMBL30168562 | 0.81 | AKR1B1 (0.47) | AKR1B1NLRP3ALOX15MAPT | |
| SCHEMBL24076971 | 0.81 | AKR1B1 (0.47) | AKR1B1NLRP3ALOX15MAPT | |
| SCHEMBL29348078 | 0.81 | ALOX15 (0.46) | AKR1B1NLRP3ALOX15AKR1B10RAB9A | |
| SCHEMBL29348083 | 0.81 | S1PR2 (0.46) | AKR1B1ALOX15RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4567028-A1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2025-06-11 | — | — | EP | disclosed |
| EP-4330235-B1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-12 | — | — | EP | disclosed |
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| EP-4330235-A1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022229315-A1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, PYCARD | AKR1B1 320/4885NLRP3 1/4885ALOX15 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.